​

Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 86.16% institutional investors, 2.28% insiders, and 11.56% retail investors. Redmile group is the largest institutional shareholder, holding 10.93% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockFate Therapeutics86.16%2.28%11.56%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group12.87M10.93%$21.24M
Blackrock10.12M10.01%$33.18M
Blackrock funding, inc. /de10.94M9.29%$18.05M
Vanguard group10.33M8.77%$17.05M
Boxer capital8.22M8.13%$26.95M
Bellevue group4.84M4.11%$7.99M
Morgan stanley3.15M3.11%$10.33M
Deerfield management company, l.p. (series c)3.56M3.02%$5.87M
Johnson & johnson3.38M2.87%$5.58M
Baker bros. advisors lp3.26M2.77%$5.38M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Superstring capital management lp1.38M1.97%$2.28M
Redmile group12.87M1.48%$21.24M
Johnson & johnson3.38M1.44%$5.58M
Boxer capital8.22M1.42%$26.95M
Vestal point capital, lp2.46M0.24%$4.07M
Tang capital management1.86M0.20%$3.06M
Ecor1 capital3.05M0.19%$5.03M
Bruce350.00K0.19%$577.50K
Bellevue group4.84M0.15%$7.99M
Sphera funds management397.18K0.12%$655.34K

Top Buyers

HolderShares% AssetsChange
Ecor1 capital3.05M0.19%3.05M
Tang capital management1.86M0.20%1.16M
Blackrock10.12M0.00%1.02M
Walleye capital1.08M0.00%1.02M
Cerity partners823.13K0.00%806.85K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---5.57M
State street2.23M0.00%-3.03M
Suvretta capital management---2.56M
Holocene advisors, lp---2.53M
Assenagon asset management372.51K0.00%-2.06M

New Positions

HolderShares% AssetsChangeValue
Ecor1 capital3.05M0.19%3.05M$5.03M
Sphera funds management397.18K0.12%397.18K$655.34K
Susquehanna fundamental investments118.19K0.00%118.19K$195.01K
Aristides capital100.56K0.03%100.56K$165.92K
Point72 asia (singapore) pte.33.09K0.01%33.09K$54.60K

Sold Out

HolderChange
Mather group, llc.-5.00
Innealta capital-9.00
Chris bulman-10.00
Nelson, van denburg & campbell wealth management group-17.00
Evermay wealth management-25.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024157-3.68%101,473,772-11.49%860.91%7620.63%47-16.07%
Sep 30, 2024163-9.94%114,640,778-6.17%970.67%63-33.68%5718.75%
Jun 30, 20241817.74%122,176,866-0.69%1200.82%956.74%48-5.88%
Mar 31, 20241687.01%123,027,79829.12%1211.30%8932.84%51-15.00%
Dec 31, 2023157-5.99%95,280,535-0.40%961.03%67-16.25%6020.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord4.84M4.25%-
Vanguard Total Stock Mkt Idx Inv3.05M2.66%-
Vanguard US Total Market Shares ETF3.05M2.66%-
iShares Russell 2000 ETF2.62M2.29%-22.71K
Vanguard Strategic Equity Inv2.54M2.23%-
SPDR® S&P Biotech ETF2.34M2.06%33.31K
JPMorgan US Small Company L1.87M1.63%1.40M
Vanguard Institutional Extnd Mkt Idx Tr1.40M1.23%-
Vanguard Explorer Inv1.27M1.11%-
Fidelity Small Cap Index973.91K0.85%-18.24K

Recent Insider Transactions

DateNameRoleActivityValue
Jan 10, 2025Bressi Jerome Charles See RemarksSell$9.27K
Jan 10, 2025TAHL CINDY See RemarksSell$8.76K
Jan 10, 2025Valamehr Bahram President and CEOSell$13.41K
Dec 20, 2024Redmile Group, LLC Buy$668.58K
Dec 20, 2024Redmile Group, LLC Sell$573.94K

Insider Transactions Trends

DateBuySell
2025 Q1-3
2024 Q411
2024 Q3-1
2024 Q2--
2024 Q1-7

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 86.16%, followed by 2.28% insiders and 11.56% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 68.48%, which Fate Therapeutics exceeds.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (12.87M shares, 10.93%), Blackrock (10.12M shares, 10.01%), and Blackrock funding, inc. /de (10.94M shares, 9.29%). Together, they hold 30.23% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Superstring capital management lp is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.97% of its assets in 1.38M Fate Therapeutics shares, valued at 2.28M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools